Table 2.
Brachial artery data by visit: (a) absolute diameters and (b) absolute change with flow and nitroglycerin
| Group | Pre-therapy | Following 6 weeks of treatment | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Diameter (mm) of the brachial artery; mean (±standard deviation (SD)) | ||||||||||
| Placebo | BL 1 | Flow 1 min | Flow 5 min | BL 2 | NTG 4 min | BL 1 | Flow 1 min | Flow 5 min | BL 2 | NTG 4 min |
| 3.77 (±0.5) | 4.14 (±0.5) | 4.00 (±0.4) | 3.86 (±0.4) | 4.53 (±0.5) | 3.76 (±0.4) | 3.99 (±0.5) | 3.92 (±0.4) | 3.81 (±0.4) | 4.43 (±0.5) | |
| RBX | 3.89 (±0.7) | 4.29 (±0.6) | 4.14 (±0.6) | 4.05 (±0.6) | 4.62 (±0.7) | 3.93 (±0.8) | 4.33 (±0.6) | 4.22 (±0.7) | 4.13 (±0.7) | 4.68 (±0.7) |
| Absolute flow-mediated and nitroglycerin-mediated change (mm); mean (±SD) | ||||||||||
| Flow 1 min | Flow 5 min | NTG 4 min | Flow 1 min | Flow 5 min | NTG 4 min | Difference in 6-week change in FMD between treatmentsa | ||||
| 1 min | 5 min | |||||||||
| Placebo | 0.37 (±0.22) | 0.24 (±0.22) | 0.63 (±0.27) | 0.24 (±0.15) | 0.16 (±0.11) | 0.58 (±0.25) | 0.13 (±0.26) (p=0.08) | 0.12 (±0.21) (p<0.02) | ||
| RBX | 0.39 (±0.21) | 0.24 (±0.20) | 0.53 (±0.30) | 0.39 (±0.24) | 0.28 (±0.26) | 0.50 (±0.31) | ||||
RBX ruboxistaurin, NTG nitroglycerin, BL1 first baseline measurement—before cuff inflation, BL2 second baseline measurement—before nitroglycerin and 20 min after cuff deflation
a
p-values for RBX drug effect in repeated measures analysis of covariance (ANCOVA)